PSD Services Using The A3G

PSD SERVICES USING THE A3G

A3G has demonstrated that it can produce very high precision data very fast. This data has been published at the RDD (Respiratory Drug Delivery) meeting in Nice, France. For those customers who do not wish to make capital investments and yet need to get high precision data quickly, there is an alternative—outsource it to Lab Automate—we become your analytical laboratory. Existing ACI methods are quite easily ported to the A3G, as internally it uses the ACI without modifying it. We work closely with customers to port the methods. If at some point of time customers require to bring the system in-house, we will sell the system to them, so that their needs continue to be met uninterrupted.

HIGH PRECISION DATA

Recovery of Beclomethasone Dipropionate (n=3)

Sample Area (mV.s)
Trial 1 Trial 2 Trial 3 Mean %RSD
Mouth Piece + Induction Port + Entrance Cone 633916 667525 694897 665446 4.59
IP 1+S0 106631 92958 100562 100050 6.85
IP 2+S1 21901 23074 24430 23135 5.47
IP 3+S2 26202 25218 24759 25393 2.90
IP 4+S3 128433 125085 125093 126203 1.53
IP 5+S4 473662 455849 465866 465125 1.92
IP 6+S5 695762 681555 693435 690250 1.10
IP 7+S6 310304 306707 309955 308988 0.64
IP 8 +S7 151644 156621 155060 154441 1.65
IP =Impaction Plate. IP1 is below Stage 0, IP2 is below Stage 1, and in this manner, finally, IP8 is below Stage 7

Recovery of Fluticasone Propionate using GSK Flovent. The sample prep was done using the A3G and the Chromatography was done by ZYDUS PHARMACEUTICALS.

(GSK Flovent pMDI) Fluticasone Propionate ACI
RUN 1 RUN 2 RUN 3 RUN 4 RUN 5 RUN 6 RUN 7 RUN 8
Sr. No. Sample name % LC-220 mcg % LC-220 mcg % LC-220 mcg % LC-220 mcg % LC-220 mcg % LC-220 mcg % LC-220 mcg % LC-220 mcg %RSD
1 Mouthpiece Adaptor 5.81 5.68 5.29 5.69 5.69 5.85 5.45 5.64 3.27
2 Induction Port 48.24 45.32 45.87 45.56 47.96 44.13 41.74 43.02 4.97
3 Cone 0.12 0.13 0.13 0.12 0.14 0.1 0.1 0.12 11.79
4 Impaction Plate-1 + Stage 0 3.03 2.83 2.88 2.76 2.9 3.06 2.69 3.45 8.04
5 Impaction Plate-2 + Stage 1 1.86 3.3 3.39 3.44 3.7 3.45 3.52 3.75 18.23
6 Impaction Plate-3 + Stage 2 5.05 5.11 5.31 5.55 5.92 5.63 5.62 5.82 5.76
7 Impaction Plate-4 + Stage 3 14.3 14.84 15.32 16.25 16.22 15.27 15.41 15.92 4.38
8 Impaction Plate-5 + Stage 4 15.05 14.95 15.5 16.32 15.86 15.39 15.49 15.78 2.86
9 Impaction Plate-6 + Stage 5 5.53 5.29 5.4 5.75 5.71 5.5 5.57 5.5 2.72
10 Impaction Plate-7 + Stage 6 0.7 0.67 0.68 0.72 0.72 0.72 0.68 0.72 3.09
11 Impaction Plate-F + Stage 7 0.2 0.28 0.2 0.25 0.28 0.27 0.24 0.24 13.09
12 Stage-F 0.17 0.22 0.24 0.25 0.22 0.2 0.19 0.21 12.26
Mass Balance 100.06 98.62 100.21 102.66 105.32 99.57 96.7 100.17 2.58


The low RSD reported for sample recovery suggest that the A3G yields reproducible data, even in locations where there is low drug deposition, because even small changes in drug recovery can result in higher RSDs.